Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medicare Value-Based Model May Provide Test For Biosimilars – At Some Point

Executive Summary

Rheumatoid arthritis will be included in broaden clinical categories for year two of the value-based insurance design pilot; it may be an interesting test case for biosimilars.

Advertisement

Related Content

AbbVie v. Amgen Round One: Humira Biosimilar Infringes 10 Patents, Suit Claims
Biosimilar Litigation: Battles Continue Over Launch Notification, Access To FDA Info
Amgen's Humira Biosimilar Gains Nod From Panel Perplexed By Regulatory Pathway
Sandoz Steers Enbrel Biosimilar Away From Equivalence Quandary With Reanalysis
CMS To Test Value-Based Insurance Design; Diabetes, COPD Among Target Diseases

Topics

What to read next

Advertisement
UsernamePublicRestriction

Register

PS119002

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel